RESPIRATORY DISEASE TESTING MARKET ANALYSIS

The global respiratory disease testing market is estimated to be valued at US$ 3,232 Million in 2023 and is expected to exhibit a CAGR of 4% during the forecast period (2023-2030).

Analysts’ Views on Global Respiratory Disease Testing Market:

Global respiratory disease testing market has gained momentum in recent times because of the increasing incidence of chronic respiratory disorders such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis. Furthermore, an increase in research & development and company initiatives are the factors for the growth of the respiratory disease testing which shows significant opportunities for global respiratory disease testing market growth over the forecast period. Investments in the development of Respiratory Disease Testing are a key trend gaining popularity in global respiratory disease testing market. major pharmaceutical companies are investing in the development of Respiratory Disease Testing to sustain its position in the market.

Figure 1. Global Respiratory Disease Testing Market Share (%), By Product Type, 2023

To learn more about this report, request a free sample copy

Global Respiratory Disease Testing Market– Driver

Rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis

Rising incidence of respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis is expected to drive the market growth over the forecast period. For instance, according to the World Health Organization, report in May 2020, asthma is the most common chronic disease among children worldwide and around 339 million people were living with asthma in 2020. Similarly, according to the same source, over 80% of asthma-related deaths occur in low-and lower-middle income countries.

Growing geriatric population

Growing geriatric population can also drive the Respiratory Disease Testing market growth. For instance, according to an article published in World Health Orgnisation, in November 2022, reported 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). Non- cystic fibrosis bronchiectasis is the most common in elderly and frailer patients with estimated cases of 50% in patients over 65 years of age and 19.1% in patients over 75 years old.

Figure 2. Global Respiratory Disease Testing Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Global Respiratory Disease Testing Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global respiratory disease testing market over the forecast period. North America is estimated to hold 38.3% of the market share North America holds a significant market share in the respiratory disease testing market worldwide, mainly due to the key market players are focusing on inorganic statergies such as merger and increased manufacturing of inhaled antibiotics. For instance, EnBiotix, Inc., a rare disease company focused on chronic respiratory disorders in the U.S., announced the closing of an US$11M pre-merger, convertible note round of financing comprised of Vectura Group plc, the Cystic Fibrosis Foundation, and Sanford Biosciences LLC is developing medicines for unmet patient needs and responding to the demand for increased access to biologic treatments. Thus, North America is also projected to spur the global inhaled antibiotics market growth over the forecast period.

Global Respiratory Disease Testing Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the respiratory disease testing market. for instance, an article published in the national library of Medicine, in August 2020, reported the prevalence of Staphylococcus aureus infection in respiratory cultures and diagnostic performance of nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia.

Global Respiratory Disease Testing Market Segmentation:

The global respiratory disease testing market report is segmented into By Test Type, By End User, and By Region.

By Test Type, the global respiratory disease testing market is segmented into Imaging test, spirometry, peak flow test, blood gas test, lung volume test, and others. Out of which, the Imaging test segment is expected to dominate the Respiratory Disease Testing market during the forecast period and this is due to the high prevelance of infectious disease.

By End User, the global respiratory disease testing market is segmented into Hospitals, Physician Offices, Clinical Laboratories. Out of which, the hospitals segment is expected to dominate the global respiratory disease testing market during the forecast period and this is attributed to the providing disease information and adequate statistics on medication consumptions.

Among all the segmentations, the Test type has the potential due to the increasing  respiratory tract infection this is expected to drive the growth of the segment over the forecast period. For instance, in September 2021, Roche, a multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics, has launched three molecular polymerase chain reaction (PCR) diagnostic test panels to detect and differentiate common respiratory pathogens at the same time.The common respiratory illnesses include influenza A, influenza B and respiratory syncytial virus (RSV); adenovirus (ADV), human metapneumovirus (hMPV) and enterovirus/rhinovirus (EV/RV); and parainfluenza 1, 2, 3 and 4.

Global Respiratory Disease Testing Market Cross Sectional Analysis:

North America is expected to dominate the global respiratory disease testing market over the forecast period, owing to factors such as the product launch is boosting the market and the rising occurrence of asthmatic diseases in the region. For instance, In October 2020, Polyphor, launched an inhaled form of the investigational antibiotic murepavadin (POL7080), which acts specifically against the bacterial strain Pseudomonas aeruginosa, which is a strain found in patients with several lung diseases, including cystic fibrosis- and non-cystic fibrosis-associated bronchiectasis. Thus, the usage of inhaled diagnostics by law enforcement agencies for alcohol and drug abuse is expected to drive the market.

Global Respiratory Disease Testing Market: Key Developments

In February 2022, Carestream Health is Medical equipment supplier in Mumbai, Maharashtra, India, announced the launch of The DRX Compass, an accurate, convenient & configurable digital radiology solution designed to provide radiologists with a whole new level of efficiency. Additionally, DRX Compass offers the versatility to build the desired configuration from a wide range of selections in detectors, tubes, generators, tables, collimators, giving Radiology facilities full control over how they can use this future-proof digital radiology technology.

In July 2022, FUJIFILM Healthcare Corporatio, an unrivaled selection of digital X-ray (digital radiography) systems, launched the FDR Cross, a hybrid c-arm and portable x-ray solution built for hospitals and ambulatory surgery centers (ASC), Two-in-One Fluoroscopy and Digital Radiography System. The ability to offset the x-ray tube from the built-in detector accommodates wireless x-ray imaging akin to that of a standard portable x-ray, including table-top, cross-table, even wheelchair, and standing chest exams.

In December 2022, Canon Inc., specializing in optical, imaging, and industrial products, such as lenses, cameras, medical equipment, scanners, printers, and semiconductor manufacturing equipment, announced the launch in July, in markets outside of Japan1, of the CXDI-Elite series of wireless digital radiography (DR2) devices, including the CXDI-720C Wireless sensor unit.

In July 2021, Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with ABSSSI caused by susceptible isolates of designated gram-positive microorganisms.

On June 06, 2023, Spexis AG , a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced the publication of preclinical results from the company’s novel class of macrocyclic, peptidomimetic antibiotics developed, in collaboration with the University of Zurich, demonstrating potent in vitro and in vivo antimicrobial activity against multidrug resistant (MDR) and extensively drug resistant (XDR) Enterobacteriaceae.

Global Respiratory Disease Testing Market: Key Trends

Increasing product approval by regulatory bodies

Increasing product approval by regulatory bodies is expected to offer lucrative growth opportunities for players in the global respiratory disease testing market. For instance, in March 2020, Quest Diagnostics, announced to launch a U.S. FDA approved coronavirus (COVID-19) test that aids the presumptive detection of nucleic acid in respiratory specimens of patients meeting the Centers for Disease Control and Prevention’s clinical criteria for COVID-19 testing. Further more, in April 2020, Raptor Pharmaceutical Corp., a biopharmaceutical company, launched its QUINSAIR (levofloxacin inhalation solution) in Germany and Denmark. It is the first fluoroquinolone to be approved as an inhaled therapy for a pulmonary disease. QUINSAIR is approved in the European Union (EU) and Canada for the management of chronic pulmonary infections caused due to Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF).

Global Respiratory Disease Testing Market: Restraint

Low adoption rate of digital radiography

Low adoption rate of digital radiography, which is expected to hinder growth of the market. Digital radiography systems have witnessed low adoption rate as these are more expensive than analog radiography systems (US$ 11,000–US$ 22,000). The cost of digital radiography equipment ranges from US$ 100,000-US$ 130, 000. For instance, According to an article published in the National Library of medicine, reported the main disadvantages of direct digital radiography are the thickness and rigidity of the digital detector, infection control, hardware and software maintenance, and the higher initial cost of the system.

Key market players are focusing on cost effective device.

Global Respiratory Disease Testing Market- Key Players

Major players operating in the global respiratory disease testing market include CareFusion Corporation, Carestream Health, Inc., COSMED, Futuremed America, Inc., GE Healthcare, MGC Diagnostics Corporation, ndd Medical Technologies, Inc., Nihon Kohden Corporation, Perkin Elmer, Inc., FUJIFILM Healthcare Corporation, Philips Healthcare,Roche Healthcare, Beckton Dickinson and Company, Koninklijke Philips N.V. ResMed Inc., Medtronic, Abbott Diagnostics,   and Quest Diagnostics.

*Definition: Respiratory disease is a medical condition that affects the structure and organs associated with respiration or breathing. Based on anatomical features, the respiratory system has been segmented into upper respiratory tract and lower respiratory tract. The upper respiratory tract comprises pharynx, larynx and nasal passages, while the lower respiratory tract includes trachea, lungs and bronchi.